Lysyl oxidase expression is an independent marker of prognosis and a predictor of lymph node metastasis in oral and oropharyngeal squamous cell carcinoma (OSCC) - PubMed (original) (raw)
. 2010 Jun 1;126(11):2653-62.
doi: 10.1002/ijc.24948.
Affiliations
- PMID: 19816945
- DOI: 10.1002/ijc.24948
Free article
Lysyl oxidase expression is an independent marker of prognosis and a predictor of lymph node metastasis in oral and oropharyngeal squamous cell carcinoma (OSCC)
Andrea Albinger-Hegyi et al. Int J Cancer. 2010.
Free article
Abstract
Proteins of the lysyl oxidase (LOX) family are important modulators of the extracellular matrix. However, they have an important role in the tumour development as well as in tumour progression. To evaluate the diagnostic and prognostic value of the LOX protein in oral and oropharyngeal squamous cell carcinoma (OSCC) we performed QRT-PCR and immunohistochemical analysis on two tissue microarrays (622 tissue samples in total). Significantly higher LOX expression was detected in high grade dysplastic oral mucosa as well as in OSCC when compared to normal oral mucosa (P < 0.001). High LOX expression was correlated with clinical TNM stage (P = 0.020), lymph node metastases for the entire cohort (P < 0.001), as well as in the subgroup of small primary tumours (T1/T2, P < 0.001). Moreover, high LOX expression was correlated with poor overall survival (P = 0.004) and disease specific survival (P = 0.037). In a multivariate analysis, high LOX expression was an independent prognostic factor, predicting unfavourable overall survival. In summary, LOX expression is an independent prognostic biomarker and a predictor of lymph node metastasis in OSCC. Moreover, LOX overexpression may be an early phenomenon in the pathogenesis of OSCC and thus an attractive novel target for chemopreventive and therapeutic strategies.
Similar articles
- Expression of lysyl oxidase is correlated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma.
Sakai M, Kato H, Sano A, Tanaka N, Inose T, Kimura H, Sohda M, Nakajima M, Kuwano H. Sakai M, et al. Ann Surg Oncol. 2009 Sep;16(9):2494-501. doi: 10.1245/s10434-009-0559-5. Epub 2009 Jun 13. Ann Surg Oncol. 2009. PMID: 19526206 - Association of expression aberrances and genetic polymorphisms of lysyl oxidase with areca-associated oral tumorigenesis.
Shieh TM, Lin SC, Liu CJ, Chang SS, Ku TH, Chang KW. Shieh TM, et al. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4378-85. doi: 10.1158/1078-0432.CCR-06-2685. Clin Cancer Res. 2007. PMID: 17671119 - Upregulated LOX and increased collagen content associated with aggressive clinicopathological features and unfavorable outcome in oral squamous cell carcinoma.
Yu M, Shen W, Shi X, Wang Q, Zhu L, Xu X, Yu J, Liu L. Yu M, et al. J Cell Biochem. 2019 Sep;120(9):14348-14359. doi: 10.1002/jcb.28669. Epub 2019 May 29. J Cell Biochem. 2019. PMID: 31140650 - The rationale for targeting the LOX family in cancer.
Barker HE, Cox TR, Erler JT. Barker HE, et al. Nat Rev Cancer. 2012 Jul 19;12(8):540-52. doi: 10.1038/nrc3319. Nat Rev Cancer. 2012. PMID: 22810810 Review. - Targeting Lysyl Oxidase Family Meditated Matrix Cross-Linking as an Anti-Stromal Therapy in Solid Tumours.
Setargew YFI, Wyllie K, Grant RD, Chitty JL, Cox TR. Setargew YFI, et al. Cancers (Basel). 2021 Jan 27;13(3):491. doi: 10.3390/cancers13030491. Cancers (Basel). 2021. PMID: 33513979 Free PMC article. Review.
Cited by
- Restoring BARX2 in OSCC reverses partial EMT and suppresses metastasis through miR-186-5p/miR-378a-3p-dependent SERPINE2 inhibition.
Sun Y, Pan J, Li Y, Hu Y, Ma J, Chen F, Zhang Y, Jiang Z, Zhang J. Sun Y, et al. Oncogene. 2024 Jun;43(25):1941-1954. doi: 10.1038/s41388-024-03053-w. Epub 2024 May 8. Oncogene. 2024. PMID: 38719950 - Cell-Cell Mechanical Communication in Cancer.
Schwager SC, Taufalele PV, Reinhart-King CA. Schwager SC, et al. Cell Mol Bioeng. 2019 Feb;12(1):1-14. doi: 10.1007/s12195-018-00564-x. Epub 2018 Dec 7. Cell Mol Bioeng. 2019. PMID: 31565083 Free PMC article. - Cancer-associated fibroblasts promote oral squamous cell carcinoma progression through LOX-mediated matrix stiffness.
Zhang JY, Zhu WW, Wang MY, Zhai RD, Wang Q, Shen WL, Liu LK. Zhang JY, et al. J Transl Med. 2021 Dec 20;19(1):513. doi: 10.1186/s12967-021-03181-x. J Transl Med. 2021. PMID: 34930321 Free PMC article. - Lysyl oxidase mediates hypoxia-induced radioresistance in non-small cell lung cancer A549 cells.
Gong C, Gu R, Jin H, Sun Y, Li Z, Chen J, Wu G. Gong C, et al. Exp Biol Med (Maywood). 2016 Feb;241(4):387-95. doi: 10.1177/1535370215609694. Epub 2015 Oct 28. Exp Biol Med (Maywood). 2016. PMID: 26515140 Free PMC article. - Interplay Between LOX Enzymes and Integrins in the Tumor Microenvironment.
Amendola PG, Reuten R, Erler JT. Amendola PG, et al. Cancers (Basel). 2019 May 26;11(5):729. doi: 10.3390/cancers11050729. Cancers (Basel). 2019. PMID: 31130685 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical